LITERATURE SEARCHES FOR THIS PPP

Literature searches of the PubMed database were conducted on March 3, 2022; the search strategies are listed below. Specific limited update searches were conducted on June 7, 2023. The searches had added filters for human, English-language randomized controlled trials and systematic reviews and date limiters to capture literature published since June 27, 2018. The panel analyzed 4,327 studies of which 50 were included in the PPP. The literature searches with the disease condition and the search term, patient values and patient preferences didn’t yield results. The literature searches for economic evaluation and treatment cost yielded 66 studies, 66 of which were provided to the panel, 1 of which merited inclusion in the PPP.

**Dry Eye All:** ("dry eye syndromes"[MeSH Terms] OR dry eye[tiab])

**Epidemiology:** ("dry eye syndromes/epidemiology"[majr:noexp]) OR ("dry eye syndromes/ethnology"[majr:noexp]) OR ((dry eye[tiab] AND (prevalence[tiab] OR epidemiolog*[tiab] OR ethn*[tiab]))

**Etiology:** ("dry eye syndromes/etiology"[majr:noexp]) OR (dry eye[tiab] AND etiolog*[tiab]))

**Risk Factors:** ("dry eye syndromes"[majr:noexp] OR dry eye[tiab]) AND ("risk factors"[MeSH Terms] OR risk factor*[tiab])

**Quality of Life:** (dry eye syndromes[majr:noexp] OR dry eye[tiab]) AND ("quality of life"[MeSH Terms] OR quality of life[tiab])

**Cost of Illness:** ("dry eye syndromes"[majr:noexp] OR dry eye[tiab]) AND ("cost of illness"[MeSH Terms] OR "cost benefit analysis"[MeSH Terms] OR cost*[tiab])

**Economics:** ("dry eye syndromes/economics"[mh:noexp]) OR (dry eye[tiab] AND economic*[tiab])

**Therapy:** ("dry eye syndromes/drug therapy"[majr:noexp] OR "dry eye syndromes/diet therapy"[majr:noexp] OR "dry eye syndromes/surgery"[majr:noexp] OR "dry eye syndromes/therapy"[majr:noexp])

**Pathology, Physiology:** ("dry eye syndromes/pathology"[MAJR:noexp]) OR ("dry eye syndromes/physiology"[MAJR:noexp]) OR ("dry eye syndromes/physiopathology"[MAJR:noexp])

**Disease Progression:** ("dry eye syndromes"[Mh:noexp] OR dry eye[tiab]) AND ("disease progression"[MeSH Terms] OR disease progress*[tiab])

**Diagnosis:** ("dry eye syndromes/diagnosis"[MAJR:noexp])

**Prevention and Control:** "dry eye syndromes/prevention and control"[MAJR]

**Quality of Life:** (“dry eye syndromes”[MESH Terms] OR “dry eye”[tiab]) AND ("quality of life"[MeSH Terms])

**Patient Values:** dry eye syndromes[tiab] AND (patient values[tiab] OR patient preferences[tiab])

For more information, visit: http://www.prisma-statement.org/